This site is intended only for healthcare professionals resident in India

Search

Menu

Close

Sign InLog Out
Our medicinesTherapy areasExplore ContentExplore contentEventsMaterialsVideosLet's connectLet's ConnectPfizer medical informationOnConnect

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

AboutEfficacySafetyDosingPortfolioSupportGroAssistEventsMaterialsVideos
GroAssist Mobile App
What Is GroAssist?​​​​​​​GroAssist is a mobile app designed specifically for parents and their children who have been
prescribed NGENLA to keep on track with injections and to support adherence to growth hormone (GH) treatment.Designed to support patients 
  • Easy-to-read graphs track your patient’s height and weight so parents and caregivers can see the progress following treatment
  • A record of injection sites and reminders helps establish an injection routine to ensure adherence to treatment
  • Injection targets keep patients motivated as they swipe to reveal their personal reward
  • Data summaries can support treatment decisions with healthcare professionals
  • Access to the app between parents and caregivers to improve continuity of care when treatment is managed between multiple caregivers
Watch this video to find out more about the key features of GroAssistHow your patients can access the app

Coming Soon...

Patients can download the app from the Google Play Store and App Store, for both Android and Apple devices—all they need to do is search for “GroAssist” and use the access code provided by their healthcare provider to register for an account.

DownloadLoadingDownloadLoading
References:Adapted from GENRYZONTM Local Product Document: LPDGEN092022.Zadik Z, Zelinska N, Iotova V, et al. Results from an open-label extension of the phase 2 dose-finding study of once weekly somatrogon vs daily Genotropin in pediatric patients with growth hormone deficiency (GHD). Poster 6887 presented at: Annual Meeting of the Endocrine Society [virtual]; March 20-23, 2021.Maniatis AK, Carakushansky M, Galcheva S, et al. Perception of treatment burden with once weekly somatrogon vs once daily Genotropin in pediatric patients with growth hormone deficiency: results from a randomized phase 3 study. Poster 6895 presented at: Annual Meeting of the Endocrine Society [virtual]; March 20-23, 2021.




 

PP-SMT-IND-0027,  05 OCT 2023

 

 EFFICACY

Height outcome comparable to daily GH in children with GH deficiency...with the benefit of fewer injections.1

 View efficacy data SAFETY

5 years of clinical safety data in children with GH deficiency.2​​​​​​​

 View safety data DOSING & ADMINISTRATION

Convenient, once-weekly administration.1,3

 See instructions
Contact Center for Health Care Professionals | Monday to Saturday 9:00 AM to 6:00 PM IST(exlcuding public holidays)

0008000503188

PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign in or RegisterSign inRegisterAccountSign OutThese pages are not intended for patients or for members of the general public. The web pages contain promotional content. For the use only of Registered Medical Practitioners or a Hospital or a Laboratory. Full prescribing information available on request. For more details on, Who is a Registered Medical Practitioner, please visit "https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf", Page No. 39, Rule 2 part (ee), last accessed on 26th April2021.

Address: The Capital,  A Wing, 1802, 18th Floor, Plot No. C-70, ‘G’ Block, Bandra Kurla Complex, Bandra East, Mumbai – 400051, India.
PP-SMT-IND-0027

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

Heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

ButtonButton

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.

Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.

Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.

Copyright © 2024 Pfizer Limited, India. All rights reserved. Applicable for Pfizer Products, Product Microsites and Therapy Areas section of the website:
  • All content published herein is intended and strictly only for informational, educational, academic and/or research purposes and shall not be utilized to diagnose or treat a health problem or disease without referring to the full prescribing information for list of approved indications as contained in the product package insert
  • While due care and caution has been taken to ensure that the content herein is free from mistakes or omissions, Pfizer makes no claims, promises or guarantees about the accuracy, completeness or adequacy of the information herein
For the use only of Registered medical practitioners* or a Hospital or a Laboratory

These pages are not intended for patients or for members of the general public. The web pages contain promotional content.

 

If you select 'No', you will be redirected to Pfizer.co.in

For more details on, Who is a Registered medical practitioner*, please visit "https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf", Page No. 39, Rule 2 part (ee), last accessed on 26th April 2021.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.


PP-DOL-IND-0642  28 May 2024Yes No
You are now leaving PfizerPro website
​
​​​​​You are now leaving Pfizer Pro website and will be redirected to another website. Note that you will be governed by the Terms & Conditions and Privacy Policy of the external website. Would you like to continue?
PP-DOL-IND-0642  28 May 2024